PTH and hypoparathyroidism: Recombinant human PTH [rhPTH(1-84)] is full-length PTH that was approved in the United States in 2015 as a once-daily subcutaneous administration as an adjunctive treatment of adults with hypoparathyroidism who could not be well controlled on conventional therapy alone26.